Clinical Trials Browser

Has results × pembrolizumab × Clear all

NCT03634241 2026-04-16

Pembrolizumab in Preventing Lung Cancer in Patients With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules, the IMPRINT-Lung Study

Phase 2 Completed

45 enrolled 9 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04924062 2026-04-15

KEYNOTE-966

Phase 3 Completed

158 enrolled 19 charts

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Bile Duct Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT05232851 2026-04-14

A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer

Phase 1/2 Active not recruiting

20 enrolled 11 charts

Carcinoma, Oropharyngeal Neoplasms

NCT02506153 2026-04-13

Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery

Phase 3 Active not recruiting

1,301 enrolled 16 charts

Melanoma

NCT03304639 2026-04-13

Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma

Phase 2 Active not recruiting

9 enrolled 11 charts

Carcinoma, Merkel Cell

NCT03390504 2026-04-13

THOR

Phase 3 Active not recruiting

629 enrolled 32 charts 1 FDA

Urothelial Cancer

NCT03914612 2026-04-13

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

Phase 3 Active not recruiting

813 enrolled 16 charts 2 FDA

GynecologicSarcoma

Carcinosarcoma, Endometrial Neoplasms

NCT04214249 2026-04-13

BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia

Phase 2 Active not recruiting

49 enrolled 32 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04216316 2026-04-13

Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer

Phase 1/2 Active not recruiting

12 enrolled 25 charts

Lung Neoplasms

NCT04225117 2026-04-13

A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

Phase 2 Active not recruiting

329 enrolled 23 charts

BreastGastrointestinalHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Triple Negative Breast Neoplasms

NCT04284787 2026-04-13

BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia

Phase 2 Active not recruiting

60 enrolled 11 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02819752 2026-04-09

PEACH

Phase 1 Terminated

3 enrolled 12 charts

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT03236935 2026-04-09

Phase Ib of L-NMMA and Pembrolizumab

Phase 1 Completed

12 enrolled 15 charts

DermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, DNA Repair-Deficiency Disorders

NCT04869137 2026-04-08

Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma

Phase 2 Active not recruiting

26 enrolled 9 charts

Skin Neoplasms, Carcinoma, Merkel Cell

NCT05077709 2026-04-08

IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC

Phase 2 Completed

63 enrolled 18 charts

Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung

NCT06099782 2026-04-08

MK-3475A-F11

Phase 2 Active not recruiting

147 enrolled 14 charts

DermatologicGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT02673333 2026-04-06

Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma

Phase 2 Active not recruiting

39 enrolled 7 charts

Adrenocortical Carcinoma

NCT03428802 2026-04-03

Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability

Phase 2 Active not recruiting

21 enrolled 9 charts

BreastGynecologic

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms

NCT02964078 2026-04-02

Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer

Phase 2 Completed

27 enrolled 10 charts

Kidney Diseases, Kidney Neoplasms, Neoplasm Metastasis

NCT03126630 2026-04-01

Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma

Phase 1/2 Active not recruiting

49 enrolled 20 charts

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT03983668 2026-03-30

CMP-001 for Relapsed and Refractory Lymphoma

Phase 1/2 Terminated

14 enrolled 11 charts

Lymphoma

NCT03386357 2026-03-27

Radiotherapy With Pembrolizumab in Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

Phase 2 Terminated

115 enrolled 15 charts

Squamous Cell Carcinoma of Head and Neck

NCT03620019 2026-03-27

Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma

Phase 2 Completed

25 enrolled 16 charts

Melanoma

NCT04199104 2026-03-27

A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)

Phase 3 Completed

511 enrolled 20 charts

Squamous Cell Carcinoma of Head and Neck

NCT04234113 2026-03-27

Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors

Phase 1 Terminated

115 enrolled 43 charts

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Ovarian Neoplasms, Stomach Neoplasms, Thymus Neoplasms, Thyroid Neoplasms, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT05036681 2026-03-27

A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma

Phase 2 Terminated

9 enrolled 10 charts

Neoplasm Metastasis, Endometrial Neoplasms

NCT03197506 2026-03-25

Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma

Phase 2 Active not recruiting

52 enrolled 19 charts

Glioblastoma, Gliosarcoma

NCT03568058 2026-03-24

Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers

Phase 1 Completed

25 enrolled 12 charts

Neoplasms

NCT04003636 2026-03-24

KEYNOTE-966

Phase 3 Completed

1,069 enrolled 19 charts 2 FDA

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Bile Duct Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT03753659 2026-03-23

IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC)

Phase 2 Completed

30 enrolled 10 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT05059470 2026-03-23

IMRT Followed by Pembrolizumab in the Adjuvant Setting in Anaplastic Cancer of the Thyroid (IMPAACT): Phase II Trial Adjuvant Pembrolizumab After IMRT in ATC

Phase 2 Terminated

6 enrolled 8 charts

Thyroid Diseases

NCT02690558 2026-03-20

Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy

Phase 2 Completed

39 enrolled 16 charts

Urinary Bladder Neoplasms

NCT02852655 2026-03-20

A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma

Phase 1 Active not recruiting

60 enrolled 19 charts

Brain Neoplasms

NCT04191096 2026-03-20

KEYNOTE-991

Phase 3 Active not recruiting

1,251 enrolled 15 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT04637594 2026-03-20

IMAGINE

Phase 3 Active not recruiting

3 enrolled 6 charts

Carcinoma, Transitional Cell

NCT03276832 2026-03-19

Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma

Phase EARLY_PHASE1 Completed

7 enrolled 11 charts

Melanoma

NCT03517449 2026-03-19

MK-3475-775

Phase 3 Completed

827 enrolled 34 charts 2 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

NCT02642809 2026-03-18

Pembrolizumab With Locally Delivered Radiation Therapy for the Treatment of Metastatic Esophageal Cancers

Phase 1 Completed

16 enrolled 13 charts

Gastrointestinal

Esophageal Neoplasms

NCT04902040 2026-03-18

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

Phase 1/2 Terminated

19 enrolled 11 charts

GenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Lung Neoplasms

NCT02504372 2026-03-17

PEARLS

Phase 3 Completed

1,177 enrolled 21 charts 2 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT02818920 2026-03-17

TOP 1501

Phase 2 Completed

35 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung

NCT03070392 2026-03-17

Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

Phase 2 Completed

378 enrolled 15 charts 2 FDA

Uveal Melanoma, Melanoma

NCT02648282 2026-03-13

Study With CY, Pembrolizumab, GVAX Pancreas Vaccine, and SBRT in Patients With Locally Advanced Pancreatic Cancer

Phase 2 Completed

58 enrolled 9 charts

Gastrointestinal

Pancreatic Neoplasms

NCT05523323 2026-03-13

A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China Extension

Phase 3 Completed

112 enrolled 16 charts

Squamous Cell Carcinoma of Head and Neck

NCT03239145 2026-03-12

Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor

Phase 1 Completed

62 enrolled 17 charts

DermatologicGastrointestinalGenitourinaryGynecologic

Kidney Neoplasms, Melanoma, Ovarian Neoplasms, Colorectal Neoplasms

NCT02402920 2026-03-10

Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer

Phase 1 Completed

83 enrolled 13 charts

Neuroendocrine Tumors

NCT03142334 2026-03-10

KEYNOTE-564

Phase 3 Completed

994 enrolled 10 charts 2 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT03833167 2026-03-10

KEYNOTE-630

Phase 3 Completed

450 enrolled 18 charts

Carcinoma, Squamous Cell

NCT02446457 2026-03-09

Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma

Phase 2 Active not recruiting

53 enrolled 10 charts

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT02858869 2026-03-09

Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases

Phase 1 Completed

25 enrolled 14 charts

CNSDermatologicThoracic

Uveal Melanoma, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma